Houston John G, Banks Martyn N, Binnie Alastair, Brenner Stephen, O'Connell Jonathan, Petrillo Edward W
Department of Applied Biotechnology, Research and Development, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA.
Drug Discov Today. 2008 Jan;13(1-2):44-51. doi: 10.1016/j.drudis.2007.11.004. Epub 2008 Jan 3.
We review strategic approaches taken over an eight-year period at BMS to implement new high-throughput approaches to lead discovery. Investments in compound management infrastructure and chemistry library production capability allowed significant growth in the size, diversity and quality of the BMS compound collection. Screening platforms were upgraded with robust automated technology to support miniaturized assay formats, while workflows and information handling technologies were streamlined for improved performance. These technology changes drove the need for a supporting organization in which critical engineering, informatics and scientific skills were more strongly represented. Taken together, these investments led to significant improvements in speed and productivity as well a greater impact of screening campaigns on the initiation of new drug discovery programs.
我们回顾了百时美施贵宝公司（BMS）在八年时间里为实施新的高通量先导化合物发现方法所采取的战略举措。对化合物管理基础设施和化学文库生产能力的投资，使BMS化合物库在规模、多样性和质量上都有了显著增长。筛选平台采用了强大的自动化技术进行升级，以支持小型化检测形式，同时简化了工作流程和信息处理技术，以提高性能。这些技术变革推动了对一个支持性组织的需求，在这个组织中，关键的工程、信息学和科学技能得到了更有力的体现。总体而言，这些投资显著提高了速度和生产率，同时筛选活动对新药发现项目启动的影响也更大。
